Psoriasis Patients in Phase 1 Trial Receiving KY1005-CT01, a Potential Bowel Disease Therapy

Psoriasis Patients in Phase 1 Trial Receiving KY1005-CT01, a Potential Bowel Disease Therapy
A 24th psoriasis patient has received KY1005-CT01 in a Phase 1 clinical trial of the treatment designed to fight the autoimmune disorder affecting the skin and other organs. KY1005 has the potential to treat several autoimmune disorders, including inflammatory bowel disease, or IBD. An autoimmune disease is one in which the immune system, whose job is to defend against invaders, attacks the body's healthy cells instead. The trial that Kymab is conducting includes healthy volunteers as well. The British company hopes to recruit 88 participants, and complete the study (NCT03161288) in 2018. Kymab designed KY1005 to block the activation of OX40, a protein that lengthens T-cells' immune response, which fosters autoimmune diseases. T-cells are a type of white blood cell. KY1005, a human monoclonal antibody, brings the immune system back into balance, restoring the healthy organ function that the autoimmune disorder disrupted. One of its advantages is that it focuses specifically on autoimmune activity, in contrast with therapies that have broader effects, including undesirable ones. The trial will evaluate the safety of KY1005, and participants' ability to tolerate it. Researchers will test several doses. The patients in the study will have mild to moderate forms of psoriasis. "I am delighted that we have reached another important milestone for Kymab," Professor Allan Bradley,  Kymab's chief medical officer, said in a press re
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *